Most neuroblastoma patients over 18 months of age at diagnosis present disseminated disease. The presence of neuroblastoma cells in bone marrow can be used to evaluate the response to treatment. It is possible that alterations in certain tumour cells might confer a selective advantage over tumour dissemination process, and probably be helpful in the clonal selection of tumour-specific cells that could originate metastasis.
Unidad de Genética y Diagnóstico Prenatal, Edificio de Anatomia Patologica, Hospital Universitario La Fe, Av/Campanar N masculine21, 46009, Valencia, Spain. elena_grau@hotmail.com
